Skip to main content

Cancer

Can the Focus Score predict Lymphoma in Sjogren’s syndrome? by Dr. Eric Dein ( @ejdein1 ) https://t.co/B5HN6ju3ru https://t.co/3MuXH66YqJ
Dr. John Cush @RheumNow( View Tweet )
Jun 09, 2021

Can the Focus Score predict Lymphoma in Sjogren’s syndrome?

Jun 08, 2021

Patients with Sjogren’s syndrome are nearly 19 times more likely to develop lymphoma, so identifying factors that impact this risk development is a major goal in caring for this disorder. Many risk factors are established such as low C4, palpable purpura, parotid gland enlargement, and

Read Article
Video: RA and Cancer: Myth or Reality? Dr. Jonathan Kay ( @RheumKay ) Dr. Kay reviewed highlights from the "Oncorheumatology: the crossroads of cancer and musculoskeletal diseases" scientific session including abstract OP0187, presented at #EULAR2021. https://t.co/KaLEZ67L5S https://t.co/6MHXyffO2W
Dr. John Cush @RheumNow( View Tweet )
Jun 07, 2021
#EULAR2021 POS0230: TNFi changes intestinal microbiota in IBD-SpA ⬇️ Proteobacteria ⬆️Lachnospiraceae, Coprococcus Does inflammatory changes by TNFi restore intestinal eubiosis and does this affect SpA outcomes? @Rheumnow

Eric Dein @ejdein1( View Tweet )

Jun 05, 2021

EULAR 2021 - Day 2 Podcasts

Jun 04, 2021

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:



1. EULAR2021 - Day2a



Read Article
⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD ⭐️No overall increase in all CA: RTX, TOCI ⭐️Abatacept 1.21HR for all cancer, mainly NMSC ⭐️needs more data on JAKs, IL-17, IL-23 Abs#6916 #EULAR2021 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 03, 2021
OP0186 #EULAR2021 by Dr. Mariele Gatto. Anti-cancer effect of immunotherapy with ICI is believed to be mediated by CD8 positive Tc cells. It is not known if other cells get activated. This study looks at B cells. Transitional B cells ⬆️ in ICI induced arthritis (CP-IA). /TK https://t.co/szFF81SKVL
ARD & RMD Open @ARD_BMJ( View Tweet )
Jun 03, 2021
Checkpoint Inhibitor Safety in Melanoma Patients with AID A study from the DMT shows that the use of checkpoint inhibitors for advanced melanoma in AID patients didn't increase the risk of irAEs, except for those with preexisting IBD. https://t.co/VFzBOlc0wc https://t.co/0zfr8YFmZr
Dr. John Cush @RheumNow( View Tweet )
May 20, 2021

Checkpoint Inhibitor Safety in Melanoma Patients with Autoimmune Disease

May 18, 2021

Immune checkpoint inhibitors (ICI) are well known to cause immune-related adverse events (irAEs). A study from the Dutch Melanoma Treatment Registry shows that the use of checkpoint inhibitors for advanced melanoma in AID (autoimmune disease) patients did not increase the risk of irAEs, except

Read Article

RheumNow Podcast – Coconspirators: RA and Lung Disease

Apr 23, 2021

Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.

Read Article
Great reminder of from Dr. Kathryn Dao, @KDAO2011 from #RNL2021 Caution! Verrucous LE can simulate skin cancer! Both can be found in photosensitivity areas! #RheumNow

Dr. John Cush @RheumNow( View Tweet )

Apr 20, 2021

Low Risk of Malignancy with Secukinumab

Apr 12, 2021

Analysis of ongoing safety from the secukinumab (SEC) drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, psoriatic arthritis (PsA) or ankylosing spondylitis (AS).



Safety data from 10,685 psoriasis, 2,523 PsA and

Read Article

RheumNow Podcast – Mistakes with Steroids

Apr 08, 2021

Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.

Read Article

Overview of New VEXAS Syndrome

Apr 08, 2021

Medscape offers up an informative overview of the newly described syndrome called VEXAS discovered by researchers at the National Institutes of Health. These patients were previously misdiagnosed with Sweets syndrome, relapsing polychondritis, myelodysplastic syndrome, MGUS, or polyarteritis

Read Article
High Risk Cancer Profiling with Inflammatory Myositis A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs). https://t.co/TjmdGtdDQG https://t.co/tlfVU031fY
Dr. John Cush @RheumNow( View Tweet )
Feb 19, 2021

High Risk Cancer Profiling with Inflammatory Myositis

Feb 18, 2021

A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs).

Read Article

Checkpoint Inhibitor Use with Pre-existing Autoimmune Disease

Feb 17, 2021

Annals of Internal Medicine reports treating advanced melanoma with immune checkpoint inhibitors (ICI) in patients with pre-existing autoimmune disease (AID) was as effective and safe in those with AID compared to those without AID, although severe colitis occurred more frequently among

Read Article
No increased risk of cancer with TNFi use in PsA patients @RWCSmtg @JointMD https://t.co/7VSI1Fd1hw
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
Danish Cohort study of 5310 cutaneous LE or SLE pts between 1995-2014 (7-8 yrs F/U and 40.724 PYs) shows an overall increased cancer risk for CLE (SIR 1.35)and SLE (1.45), esp a 3-4 fold increased risk for NHL, hematological, pancreatic and lung cancers https://t.co/0FialHXVvb

Dr. John Cush @RheumNow( View Tweet )

Feb 09, 2021
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib when given to at-risk RA patients. https://t.co/RJD8CMouHK https://t.co/j8DMyxsaaf
Dr. John Cush @RheumNow( View Tweet )
Feb 08, 2021
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz) when given to at-risk rheumatoid arthritis patients. https://t.co/RJD8CMouHK https://t.co/bipwWlIhiB
Dr. John Cush @RheumNow( View Tweet )
Feb 05, 2021

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Feb 05, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jan 27, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.



Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

Read Article

Lung Cancer Survival With Autoimmune Disease

Dec 15, 2020

Lung cancer risk is often increased with inflammation and autoimmune disease; a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.

Read Article
#BestACR20Tweets "RT @drdavidliew : Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/x7DLzZcn9o https://t.co/OmpTAorA13
Dr. John Cush @RheumNow( View Tweet )
Dec 05, 2020
×